Guangzhou Boji Medical and Biotechnological Co Ltd (300404) — Net Asset Quality Index
Guangzhou Boji Medical and Biotechnological Co Ltd (300404) has a Net Asset Quality Index of 65.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.67 Billion minus total liabilities of CN¥569.21 Million yields net assets of CN¥1.10 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check asset resilience ratio of Guangzhou Boji Medical and Biotechnologi to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Guangzhou Boji Medical and Biotechnological Co Ltd Net Asset Quality Index Over Time (2012–2025)
This chart shows how Guangzhou Boji Medical and Biotechnological Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the index stands at 65.9%, representing net assets of CN¥1.10 Billion against total assets of CN¥1.67 Billion CNY. See Guangzhou Boji Medical and Biotechnologi short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Guangzhou Boji Medical and Biotechnological Co Ltd (2012–2025)
The table below presents the year-by-year Net Asset Quality Index for Guangzhou Boji Medical and Biotechnological Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Guangzhou Boji Medical and Biotechnologi (300404) total market value.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 65.0% | CN¥1.06 Billion | CN¥1.63 Billion | CN¥569.88 Million | ▼ -4.0 pp |
| 2024 | 69.1% | CN¥1.00 Billion | CN¥1.45 Billion | CN¥448.84 Million | ▲ +0.5 pp |
| 2023 | 68.6% | CN¥980.11 Million | CN¥1.43 Billion | CN¥448.82 Million | ▼ -1.6 pp |
| 2022 | 70.2% | CN¥888.72 Million | CN¥1.27 Billion | CN¥376.71 Million | ▼ -4.1 pp |
| 2021 | 74.4% | CN¥846.38 Million | CN¥1.14 Billion | CN¥291.83 Million | ▲ +9.7 pp |
| 2020 | 64.7% | CN¥485.00 Million | CN¥749.63 Million | CN¥264.64 Million | ▼ -7.3 pp |
| 2019 | 72.0% | CN¥456.08 Million | CN¥633.08 Million | CN¥177.00 Million | ▲ +2.1 pp |
| 2018 | 69.9% | CN¥423.71 Million | CN¥606.02 Million | CN¥182.31 Million | ▼ -2.2 pp |
| 2017 | 72.1% | CN¥414.35 Million | CN¥574.72 Million | CN¥160.37 Million | ▼ -10.7 pp |
| 2016 | 82.8% | CN¥429.84 Million | CN¥518.85 Million | CN¥89.01 Million | ▼ -0.3 pp |
| 2015 | 83.2% | CN¥432.68 Million | CN¥520.15 Million | CN¥87.47 Million | ▲ +12.8 pp |
| 2014 | 70.4% | CN¥218.48 Million | CN¥310.26 Million | CN¥91.78 Million | ▲ +0.4 pp |
| 2013 | 70.0% | CN¥205.52 Million | CN¥293.64 Million | CN¥88.12 Million | ▼ -3.0 pp |
| 2012 | 73.0% | CN¥170.36 Million | CN¥233.40 Million | CN¥63.04 Million | — |